FDA Warning Letter

Warning Letter to Zoll Medical for Major QMS Violations

The U.S. Food and Drug Administration has issued a Warning Letter to ZOLL Medical Corporation citing significant Quality System Regulation (QSR) violations involving corrective and preventive action (CAPA), complaint handling, risk management, design validation, supplier controls, and Medical Device Reporting (MDR) requirements.

The Warning Letter follows an FDA inspection conducted between February and April 2025 at ZOLL’s Chelmsford, Massachusetts facility, where the company manufactures several critical-care medical devices, including X Series defibrillators, MRI-compatible ventilators, OneStep electrodes, and AccuVent sensors.

FDA concluded that the devices were adulterated under the Federal Food, Drug, and Cosmetic Act because the firm’s quality system did not conform to applicable regulatory requirements.

CAPA and Complaint Handling Deficiencies

A central theme throughout the Warning Letter is FDA’s concern that ZOLL’s quality system failed to adequately identify, investigate, and escalate quality issues through its CAPA process.

The agency cited multiple examples where complaint data, product failures, and safety-related events did not result in CAPA investigations despite potential risks to patients.

FDA also challenged the effectiveness of the company’s complaint trending practices, noting that classifications such as “No Fault Found,” “No Product Returned,” and “User Error” may have prevented recurring issues from being properly identified and addressed.

According to FDA, several complaint trends involving ventilators, monitoring systems, and sensor performance issues were not adequately escalated despite known hazards and documented field complaints.

MRI-Compatible Ventilator Validation Questioned

FDA also cited deficiencies involving design validation of ZOLL’s MRI-compatible ventilators.

The agency stated that MRI compatibility testing was performed using a 3 Tesla MRI environment, but the company did not adequately justify or validate use in 1.5 Tesla MRI environments despite product labeling and customer use in those settings.

The Warning Letter references customer complaints involving imaging interference and ventilator performance concerns associated with MRI use.

FDA’s findings suggest the agency believes the design validation process did not fully evaluate all intended operating conditions before commercialization.

Risk Management Process Under Scrutiny

Several observations focus on the company’s risk management practices. FDA challenged the adequacy of risk analyses, hazard evaluations, and health risk assessments used to evaluate field performance issues.

In multiple cases, the agency concluded that complaint histories and real-world device performance data were not fully incorporated into risk evaluations, potentially leading to underestimation of product risks.

The findings are particularly notable as manufacturers transition from the legacy Quality System Regulation to FDA’s new Quality Management System Regulation (QMSR), which aligns more closely with ISO 13485 and places greater emphasis on risk-based quality management principles.

Medical Device Reporting Violation

FDA also cited a Medical Device Reporting violation involving an MRI-related ventilator malfunction.

According to the Warning Letter, the company became aware of an event in June 2024 that FDA believes met MDR reporting requirements. However, the corresponding MDR was not submitted until March 2025, well beyond the 30-day reporting timeframe required under FDA regulations.

The agency stated that the ventilator involved is a life-supporting device and that a recurrence of the malfunction could potentially contribute to serious injury or death.

Software Regulatory Questions

In the Warning Letter, FDA questioned whether ZOLL’s RescueNet Live software may itself meet the definition of a medical device.

According to FDA, the software appears to analyze monitoring data and generate secondary alarms rather than simply displaying information generated by other devices.

The agency indicated that if this interpretation is correct, the software may require appropriate premarket clearance or approval.

Why This Matters

While the Warning Letter identifies numerous individual violations, the broader regulatory significance lies in FDA’s concern regarding the effectiveness of the company’s overall quality management system.

The agency’s observations span nearly every major postmarket quality subsystem. CAPA, complaint handling, risk management, design validation, supplier controls, and medical device reporting.

Collectively, these findings suggest FDA believes important safety and performance signals were not consistently identified, escalated, or addressed through the company’s quality processes.

MDP Regulatory Intelligence Perspective

The Warning Letter serves as a reminder that FDA increasingly expects manufacturers to operate integrated quality systems where complaint handling, CAPA, risk management, supplier oversight, design controls, and postmarket surveillance function as interconnected processes rather than isolated activities.

Particularly notable is FDA’s focus on complaint coding practices and the agency’s concern that classifications such as “No Fault Found” and “User Error” may obscure emerging trends if not carefully evaluated.

As the industry continues to transition to QMSR requirements, manufacturers should review their complaint trending methodologies, CAPA escalation criteria, risk management processes, and MDR decision-making frameworks to ensure that real-world performance data is being effectively incorporated into quality system activities.

The Warning Letter demonstrates that FDA continues to view postmarket quality data as a critical source of risk information and expects manufacturers to use that information proactively to identify and address potential safety concerns.

Links

Read the FDA’s announcement here.